Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine with Reduced BUCY2 Conditioning for ALL
NCT03339700Phase 2Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in acute lymphoblastic leukemia (ALL), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03339700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339700.